Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Drew

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Cell Chemical Biology|December 2, 2019
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 ComplexJessie Hao-Ru Hsu, Timothy Rasmusson, James Robinson, et al.
Science Translational Medicine|May 1, 2020
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumorsErica Banks, Michael Grondine, Deepa Bhavsar, et al.
Journal for Immunotherapy of Cancer|July 31, 2020
Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunityAlexandra Borodovsky, Christine M Barbon, Yanjun Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingUltan McDermott, Sreenath V Sharma, Lori Dowell, et al.
Cell Reports|May 3, 2018
CSF1R<sup>+</sup> Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous SubtypeJuliana B Candido, Jennifer P Morton, Peter Bailey, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Journal of Medicinal Chemistry|November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell LymphomaJames S Scott, Sébastien L Degorce, Rana Anjum, et al.
Journal of Medicinal Chemistry|October 14, 2021
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target EngagementBernard Barlaam, Chris De Savi, Allan Dishington, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological MalignanciesBernard Barlaam, Robert Casella, Justin Cidado, et al.
Cancer Discovery|March 8, 2024
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug CombinationsAzadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Cell Chemical Biology|December 2, 2019
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 ComplexJessie Hao-Ru Hsu, Timothy Rasmusson, James Robinson, et al.
Science Translational Medicine|May 1, 2020
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumorsErica Banks, Michael Grondine, Deepa Bhavsar, et al.
Journal for Immunotherapy of Cancer|July 31, 2020
Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunityAlexandra Borodovsky, Christine M Barbon, Yanjun Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingUltan McDermott, Sreenath V Sharma, Lori Dowell, et al.
Cell Reports|May 3, 2018
CSF1R<sup>+</sup> Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous SubtypeJuliana B Candido, Jennifer P Morton, Peter Bailey, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Journal of Medicinal Chemistry|November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell LymphomaJames S Scott, Sébastien L Degorce, Rana Anjum, et al.
Journal of Medicinal Chemistry|October 14, 2021
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target EngagementBernard Barlaam, Chris De Savi, Allan Dishington, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological MalignanciesBernard Barlaam, Robert Casella, Justin Cidado, et al.
Cancer Discovery|March 8, 2024
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug CombinationsAzadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, et al.
Pageof 5